← All indications
Candidiasis
Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)
Subtype terms (5)
More specific conditions that are subtypes of Candidiasis in the MeSH hierarchy.
- Candidiasis, Chronic Mucocutaneous
1 drug approved
- Candidiasis, Cutaneous
1 drug approved
- Candidiasis, Invasive
18 drugs (14 approved, 4 experimental)
- Candidiasis, Oral
29 drugs (16 approved, 13 experimental)
- Candidiasis, Vulvovaginal
44 drugs (19 approved, 25 experimental)
Drugs by status
Approved for this indication (19)
Phase 4 trials (6)
Phase 2 trials (6)
Organizations
Organization Involved with Phase 4 Indications (29)
- Astellas
- Gilead Sciences
- Bayer
- Laboratorios Ordesa
- Medinova AG
- Shanghai Shyndec Pharmaceutical Co.,Ltd.
- National Institute of Allergy and Infectious Diseases (NIAID)
- University of Pennsylvania
- Allergy & Asthma Medical Group & Research Center
- Kyoto University
- Mahidol University
- Melbourne Health
- Mycoses Study Group
- Radboud University
- University of Groningen
- University of Milan
- University of Bari
- Capital Medical University
- Netherlands Organisation for Scientific Research
- Peking University
- Ginemed Sevilla
- St. Antonius Hospital, Nieuwegein
- Federation of Associations of Hospital Doctors on Internal Medicine (FADOI) Foundation
- Janssen Pharmaceutica NV
- University of Texas at Houston
- Muhimbili University
- Washington University in St. Louis
- Clever Instruments S.L.
- Johnson and Johnson
Organization Involved with Phase 3 Indications (41)
- PPD
- Basilea Pharmaceutica
- Valerio
- ProFem GmbH
- Scynexis, Inc.
- Sponsor GmbH
- Boehringer Ingelheim
- Probionov
- Zodiac Produtos Farmaceuticos S.A.
- AIDS Clinical Trials Group
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- Case Western Reserve University
- Duke University
- Indian Council of Medical Research
- Institut National de la Santé Et de la Recherche Médicale, France
- Parirenyatwa Hospital
- Assiut University
- All India Institute of Medical Sciences
- University of Vienna
- Food and Drug Administration
- Centro Universitário
- Cidara Therapeutics
- University of Malawi
- National Taiwan University
- Joint Clinical Research Centre, Kampala, Uganda
- University of Sao Paulo
- Eastman Dental Hospital
- National AIDS Research Institute, Pune
- Charles University
- +11 more
Organization Involved with Phase 2 Indications (19)
- Bristol-Myers Squibb
- Almirall
- Amplyx Pharmaceuticals
- Ferrer Internacional S.A.
- J. Uriach and Company
- Matinas Biopharma, Inc
- MethylGene Inc.
- NovaDigm Therapeutics, Inc.
- Viamet
- Pacgen Biopharmaceuticals Corporation
- Pulmocide Ltd
- Bambino Gesù Hospital and Research Institute
- Texas A&M University
- Fudan University
- Hebrew University
- ethica Clinical Research Inc.
- Shijiazhuang Pharma Group (CSPC)
- CelaCare Technologies, Inc.
- IQVIA
Organization Involved with Phase 1 Indications (16)
Organization Involved with Other Experimental Indications (18)
- Perrigo
- Lesaffre International
- Pileje
- Swiss National Science Foundation
- Cairo University
- Summa Health System
- University of Science Malaysia
- Yuzuncu Yıl University
- Wenzhou Medical University
- University of Copenhagen
- Emek Medical Center
- Medical University of Vienna
- Procter and Gamble
- Biofortis
- Eurofins
- University of Antwerp
- Shanghai Pudong Nanhui Mental Health Center
- Synbio Tech